This review demonstrates the role of mass spectrometry in detecting monoclonal proteins in multiple myeloma, highlighting its sensitivity compared to conventional methods.
Key Points
Mass spectrometry shows greater sensitivity in detecting monoclonal proteins than traditional methods.
It quantifies proteins with sensitivity surpassing BM-based assessments, enhancing early detection capabilities.
Research into optimal timing for MS evaluation indicates its importance in response assessment for multiple myeloma.
Transition to commercial availability enhances access to mass spectrometry for clinical monitoring of multiple myeloma.